Posts Tagged ‘biotech’

  Now that August is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in July – they’re ranked in order of popularity, with number one being the most viewed piece. 

<   The work we’re doing for life sciences and healthcare companies continues to pay off. And, Oracle thinks so, too. We recently received an award from Oracle’s Health Sciences Global Business Unit for the work we’re doing with their clinical and pharmacovigilance applications. 

One of my LinkedIn contacts shared the video Risk-Based Monitoring vs Remote Monitoring Finally Explained, in which Dan Sfera of www.theclinicaltrialsguru.com explains both concepts in layman’s terms. In essence, the idea of Risk-Based Monitoring (RBM) is to leverage the data in existing IT systems to spot, rectify, and prevent issues relating to the execution of […]

  Several months ago we delivered a webinar on 21 CFR Part 11, based on a recent blog series. During the Q&A session at the end, someone asked the following question: Regarding “the organization” that needs to inform the FDA of the intended use of electronic signatures, in a CRO/Sponsor relationship, who is responsible: the […]

Editorial Credit: Gil C / Shutterstock.com Analyzing Google searches to uncover previously unknown adverse events isn’t news, per se, but it looks like it could be gaining traction with the FDA. According to a recent Bloomberg article, the FDA’s public calendar shows that several employees from Google met with the FDA to discuss the possibility […]

  When you think of a pharmaceutical companies, you think drugs. You think of them as a business – drugs being developed, sold, and consumed. Not often do you think of them as do-gooders. 

  According to analysts from Credit Suisse, the prices of brand name drugs are significantly increasing, due to fast-approaching patent expiration dates and the desire to capitalize on recent approvals. Of the 140 drugs the company tracks, 43 have had a price increase in the second quarter of 2015, setting a record for the most […]

  Most of us “regular people” refer to pharmaceutical products by their trade name, but that’s not the case among life sciences professionals in research and development departments. In fact, during a product’s lifecycle, chances are it has been referred to by at least four names: a chemical compound, a company code, a generic name, […]

  Eleven pharma and biotech companies appeared on this year’s Fortune 500 list. While there are additional organizations (e.g., Procter & Gamble) that manufacturer medicines on the list, they weren’t classified as pharmaceutical companies in the ranking. These are the drug companies that made this year’s list, ranked by total annual revenue: 

Photo Credit: Maglara / Shutterstock.com My colleague, Beth Martin, wrote a great blog post today about the benefits of using Google Search for Work. What is Google Search for Work, you ask? Think of it as using Google to search the Internet, except that you search your company’s systems instead. Take a look at the infographic below, which […]

  On Thursday, April 23, 2015, we delivered a webinar on 21 CFR Part 11, based on a recent blog series. During the Q&A session at the end, someone asked the following question: In one of the initial slides, you mentioned that documents attached to emails do not fall under 21 CFR Part 11. Could […]

  Sponsors are known to work with multiple contract research organizations (CROs). And, depending on the agreement in place with each CRO, data can be captured in either the sponsor’s systems (CDMS and/or EDC) or the CRO’s. If the data is stored in CRO databases, there may come a time when it needs to be […]